These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

298 related items for PubMed ID: 28641556

  • 1. Pharmacogenetic and Pharmacokinetic Dose Individualization of the Taxane Chemotherapeutic Drugs Paclitaxel and Docetaxel.
    Andriguetti NB, Raymundo S, Antunes MV, Perassolo MS, Verza SG, Suyenaga ES, Linden R.
    Curr Med Chem; 2017; 24(33):3559-3582. PubMed ID: 28641556
    [Abstract] [Full Text] [Related]

  • 2. Metabolism of the taxanes including nab-paclitaxel.
    Joerger M.
    Expert Opin Drug Metab Toxicol; 2015 May; 11(5):691-702. PubMed ID: 25394848
    [Abstract] [Full Text] [Related]

  • 3. Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.
    Krens SD, McLeod HL, Hertz DL.
    Pharmacogenomics; 2013 Apr; 14(5):555-74. PubMed ID: 23556452
    [Abstract] [Full Text] [Related]

  • 4. Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel--a review.
    de Weger VA, Beijnen JH, Schellens JH.
    Anticancer Drugs; 2014 May; 25(5):488-94. PubMed ID: 24637579
    [Abstract] [Full Text] [Related]

  • 5. Exploring pharmacogenetics of paclitaxel- and docetaxel-induced peripheral neuropathy by evaluating the direct pharmacogenetic-pharmacokinetic and pharmacokinetic-neuropathy relationships.
    Hertz DL.
    Expert Opin Drug Metab Toxicol; 2021 Feb; 17(2):227-239. PubMed ID: 33401943
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic and Pharmacogenetic Markers of Irinotecan Toxicity.
    Hahn RZ, Antunes MV, Verza SG, Perassolo MS, Suyenaga ES, Schwartsmann G, Linden R.
    Curr Med Chem; 2019 Feb; 26(12):2085-2107. PubMed ID: 29932028
    [Abstract] [Full Text] [Related]

  • 7. Preclinical pharmacology of the taxanes: implications of the differences.
    Gligorov J, Lotz JP.
    Oncologist; 2004 Feb; 9 Suppl 2():3-8. PubMed ID: 15161985
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Role of TDM-based dose adjustments for taxane anticancer drugs.
    Muth M, Ojara FW, Kloft C, Joerger M.
    Br J Clin Pharmacol; 2021 Feb; 87(2):306-316. PubMed ID: 33247980
    [Abstract] [Full Text] [Related]

  • 10. Treatment regimens of classical and newer taxanes.
    Joerger M.
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):221-33. PubMed ID: 26589792
    [Abstract] [Full Text] [Related]

  • 11. Comparative transplacental transfer of taxanes using the human perfused cotyledon placental model.
    Berveiller P, Vinot C, Mir O, Broutin S, Deroussent A, Seck A, Camps S, Paci A, Gil S, Tréluyer JM.
    Am J Obstet Gynecol; 2012 Dec; 207(6):514.e1-7. PubMed ID: 23174392
    [Abstract] [Full Text] [Related]

  • 12. In vivo imaging as a pharmacodynamic marker.
    van der Veldt AA, Lammertsma AA.
    Clin Cancer Res; 2014 May 15; 20(10):2569-77. PubMed ID: 24831279
    [Abstract] [Full Text] [Related]

  • 13. Update on taxane development: new analogs and new formulations.
    Yared JA, Tkaczuk KH.
    Drug Des Devel Ther; 2012 May 15; 6():371-84. PubMed ID: 23251087
    [Abstract] [Full Text] [Related]

  • 14. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S, Bear HD.
    Surg Clin North Am; 2003 Aug 15; 83(4):943-71. PubMed ID: 12875604
    [Abstract] [Full Text] [Related]

  • 15. Lessons learned from development of docetaxel.
    Strother RM, Sweeney C.
    Expert Opin Drug Metab Toxicol; 2008 Jul 15; 4(7):1007-19. PubMed ID: 18624687
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity.
    Hammann F, Gotta V, Conen K, Medinger M, Cesana P, Rochlitz C, Taegtmeyer AB.
    Br J Clin Pharmacol; 2017 Apr 15; 83(4):927-930. PubMed ID: 27868228
    [Abstract] [Full Text] [Related]

  • 17. Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity.
    Jabir RS, Naidu R, Annuar MA, Ho GF, Munisamy M, Stanslas J.
    Pharmacogenomics; 2012 Dec 15; 13(16):1979-88. PubMed ID: 23215890
    [Abstract] [Full Text] [Related]

  • 18. Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination.
    de Bree E, Rosing H, Michalakis J, Romanos J, Relakis K, Theodoropoulos PA, Beijnen JH, Georgoulias V, Tsiftsis DD.
    Eur J Surg Oncol; 2006 Aug 15; 32(6):666-70. PubMed ID: 16618534
    [Abstract] [Full Text] [Related]

  • 19. Docetaxel: overview of an active drug for breast cancer.
    Crown J.
    Oncologist; 2001 Aug 15; 6 Suppl 3():1-4. PubMed ID: 11346677
    [Abstract] [Full Text] [Related]

  • 20. Dosing considerations for obese patients receiving cancer chemotherapeutic agents.
    Hall RG, Jean GW, Sigler M, Shah S.
    Ann Pharmacother; 2013 Dec 15; 47(12):1666-74. PubMed ID: 24259627
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.